0000000000223895

AUTHOR

Laura Algeri

showing 9 related works from this author

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

2023

BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with aveluma…

Cancer Researchpredictive factorsOncologyskin cancer non melanomaavelumabimmunotherapybody mass index - BMIMerkel cell carcinoma (MCC)Frontiers in Oncology
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct

Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography

2022

The volume estimation of retroperitoneal sarcoma (RPS) is often difficult due to its huge dimensions and irregular shape; thus, it often requires manual segmentation, which is time-consuming and operator-dependent. This study aimed to evaluate two fully automated deep learning networks (ENet and ERFNet) for RPS segmentation. This retrospective study included 20 patients with RPS who received an abdominal computed tomography (CT) examination. Forty-nine CT examinations, with a total of 72 lesions, were included. Manual segmentation was performed by two radiologists in consensus, and automatic segmentation was performed using ENet and ERFNet. Significant differences between manual and automat…

Fluid Flow and Transfer ProcessesTechnologyArtificial intelligenceSoft tissue sarcomaQH301-705.5Process Chemistry and TechnologyTPhysicsQC1-999General EngineeringDeep learningEngineering (General). Civil engineering (General)Computer Science ApplicationsChemistrySegmentationVolume estimationGeneral Materials ScienceDeep learning; soft tissue sarcoma; volume estimation; segmentation; artificial intelligenceTA1-2040Biology (General)InstrumentationQD1-999
researchProduct

1535P Exploring the dynamic crosstalk between immune system and genetics in a cohort of 116 completely resected gastrointestinal stromal tumors (GIST…

2021

Crosstalk (biology)Immune systemOncologybusiness.industryCohortmedicineCancer researchGastrointestinal stromal tumors (GISTs)Hematologymedicine.diseasebusinessAnnals of Oncology
researchProduct

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestin…

2021

Background: Although the gastrointestinal stromal tumor (GIST) genotype is not currently included in risk-stratification systems, a growing body of evidence shows that the pathogenic variant (PV) type and codon location hold a strong prognostic influence on recurrence-free survival (RFS). This information has particular relevance in the adjuvant setting, where an accurate prognostication could help to better identify high-risk tumors and guide clinical decision-making. Materials and Methods: Between January 2005 and December 2020, 96 patients with completely resected GISTs harboring a KIT proto-oncogene receptor tyrosine kinase ( KIT) exon 11 PV were included in the study. We analyzed the t…

KIT proto-oncogene receptor tyrosine kinaseGiSTbusiness.industryplatelet-derived growth factor receptor alphaPlatelet-Derived Growth Factor Receptor AlphaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasegastrointestinal stromal tumorExon557/558 deletionOncologyRecurrence free survivalGenotypeCancer researchmedicinePrognostic biomarkerGastrointestinal stromal tumors (GISTs)Stromal tumorprognostic biomarkerbusinessRC254-282Therapeutic Advances in Medical Oncology
researchProduct

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastat…

2020

Introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival in advanced RCC patients, but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition. This variability of clinical response makes necessary the discovery of predictive biomarkers for patient selection. Previous findings showed that the epigenetic modifications, including an extensive microRNA-mediated regulation of tumor suppressor genes, are key features of RCC. Based on this biological background, we hypothesized that a miRNA expression profile directly identified in the peripheral lymphocytes of the patients before and a…

PD-L10301 basic medicinerenal cell carcinomaCancer Researchmedicine.medical_treatmentLymphocytelcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicineRenal cell carcinomaPD-L1PD-1microRNAmedicineEpigeneticsmiRNAmicroRNAbiologybusiness.industrysoluble immune checkpointsImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePredictive biomarker030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbiology.proteinNivolumabbusinessReprogrammingCancers
researchProduct

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

2022

Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlight…

Cancer Researchimmune systemOncologytarget therapytumor microenvironmentimmunotherapyimmune checkpointssarcomasGIST
researchProduct

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement

2022

Background: Classic Kaposi’s sarcoma (CKS) is a rare, multifocal, endothelial cell neoplasm that typically occurs in elderly people with previous infection by human herpes virus-8. Prospective trials are rare, and the choice of drugs relies on prospective trials performed on HIV-associated Kaposi’s sarcoma (KS). Pegylated liposomal anthracyclines and taxanes are considered the standard first- and second-line chemotherapy, respectively. Despite the indolent biologic behavior, the natural history is characterized by recurrent disease. This condition of chronic administration of cytotoxic drugs is often associated with immediate/long-term adverse events. Methods: This was an observational, ret…

Kaposi’s sarcomaOncologygemcitabine
researchProduct

1543P Gemcitabine in classic Kaposi’s sarcoma: A pilot study

2021

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineClassic Kaposi's sarcomaHematologybusinessGemcitabinemedicine.drugAnnals of Oncology
researchProduct